{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.6","value":"63.4"},{"groupId":"OG001","spread":"34.3","value":"66.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"title":"7-day post-infusion AUC (AUC(d0-7)) - Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.2","value":"77.6"},{"groupId":"OG001","spread":"37.9","value":"72.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"title":"AUC(d0-7) - Cycle 1, Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.5","value":"73.2"},{"groupId":"OG001","spread":"26.4","value":"72.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"title":"AUC(d0-7) - Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.6","value":"87.9"},{"groupId":"OG001","spread":"30.9","value":"81.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"title":"AUC(d0-7) - Cycle 2, Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.8","value":"98.1"},{"groupId":"OG001","spread":"40.3","value":"91.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"14-day post-infusion AUC (AUC(d0-14)) - Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.8","value":"113.0"},{"groupId":"OG001","spread":"41.5","value":"109.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"AUC(d0-14) - Cycle 2, Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"description":"AUC was derived from the PK blood samples collected.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG000","title":"Enfortumab Vedotin - Cohort 1"},{"description":"Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG001","title":"Enfortumab Vedotin - Cohort 2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, monomethyl auristatin E (MMAE) or total antibody (Tab) concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, 'Number Analyzed'= participants evaluable at specified timepoints.","reportingStatus":"POSTED","timeFrame":"AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)","title":"PK Parameter for TAb: AUC (Serum)","type":"SECONDARY","unitOfMeasure":"Day*microgram per milliliter"}